Physician profile
Rebekah E Rayner
NPI 1306361928
$2,065.05
in general payments reported to CMS, 2019-2025
21 companies · $97.61 in 2025
The $97.61 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $642 · 2022: $556 · 2023: $580 · 2024: $190 · 2025: $97.61.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $867.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $867.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $311.17 | 2022-2023 | |
| Novo Nordisk INC | $306.24 | 2021-2023 | Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $211.38 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $189.33 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $182.70 | 2021-2024 | Trintellix |
| Lilly USA, LLC | $173.12 | 2021-2023 | Jardiance, Mounjaro, Emgality |
| Glaxosmithkline, LLC. | $160.04 | 2021-2023 | Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.90 | 2021-2024 | Ofev, Jardiance, Synjardy |
| Astrazeneca Pharmaceuticals LP | $96.77 | 2021-2024 | Airsupra, Farxiga |
| Amgen INC. | $89.90 | 2021-2024 | Repatha, Otezla |
| Amarin Pharma, INC. | $28.92 | 2021 | |
| Genentech USA, INC. | $23.73 | 2021 | |
| Astellas Pharma US INC | $22.93 | 2024 | Veozah |
| Sanofi-Aventis U.S. LLC | $20.74 | 2022 | |
| Paratek Pharmaceuticals, INC. | $20.01 | 2023 | Nuzyra |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $19.86 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $18.35 | 2023 | Rexulti |
| Boston Scientific Corporation | $16.09 | 2023 | Watchman Access System |
| Tolmar, INC. | $14.05 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.15 | 2024 | Trulance, Xifaxan |
| Biohaven Pharmaceuticals, INC. | $12.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rebekah Rayner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.